Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > 1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1)

1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1)

pharmaceutical raw materials
1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1) structure

1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1) 

structure
  • CAS No:

    138786-67-1

  • Formula:

    C16H15F2N3O4S.Na

  • Chemical Name:

    1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1)

  • Synonyms:

    1H-Benzimidazole,6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-,sodium salt (1:1);1H-Benzimidazole,5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-,sodium salt;Pantoprazole sodium;Protonix;Controloc;Pantoloc;Pantoprazole sodium salt;Zurcal;5-Difluoromethoxy-2-[[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole sodium salt;Pantecta;Nolpaza;Somac;142678-34-0;226904-33-2

  • Categories:

    Active Pharmaceutical Ingredients  >  Digestive System Drugs

Description

Pantoprazole sodium salt(SKF96022; Protonix) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.IC50 value:Target: proton pump inhibitor

1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1) Basic Attributes

405.35

405.05700

1312995-182-4

2933990090

Characteristics

90.8

3.53580

white to off-white solid

>130 °C (decomp)

586.9°C at 760 mmHg

308.7ºC

-20°C Freezer

Safety Information

20/21/22-37/38-41-48

22-26-36/37/39-45

Xn

1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1) Use and Manufacturing

Gastrointestinal

Drug Function and Efficacy

This product acts specifically on the gastric mucosal parietal cells, reducing the activity of H/KATPase in the parietal cells, thereby inhibiting the secretion of gastric acid. Compared with omeprazole and lansoprazole, this product has a weaker inhibitory effect on cytochrome P450-dependent enzymes. No adverse effects were found in either short-term or long-term administration of pantoprazole. This drug is non-carcinogenic, does not impair fertility, and does not induce teratogenesis. After 2.5 years of continuous medication, there were no changes in various experimental parameters of liver enzymology and cholesterol metabolism.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • AZICO BIOPHORE INDIA PRIVATE LTD

    United States United States
    Active
  • MANKIND PHARMA LTD

    United States United States
    Active
  • METROCHEM API PRIVATE LTD

    United States United States
    Active

Recommended Suppliers of 1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1)

Latest News on 1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.